Development of therapeutic mAb and ADCs
Description
For the early stage development of monoclonal therapeutic antibodies and antibody-drug conjugates (ADC), lead candidates are thoroughly probed employing a broad portfolio of bioanalytical methods. Therein, molecules are additionally exposed to various stress conditions to determine their robustness and to select the most stable candidates.
Key Data
Projectlead
Project status
completed, 03/2021 - 12/2022
Institute/Centre
Institute of Chemistry and Biotechnology (ICBT)
Funding partner
Third party